Aytu Bioscience (NASDAQ:AYTU) issued its earnings results on Thursday. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.35) by ($0.37), Bloomberg Earnings reports. Aytu Bioscience had a negative net margin of 217.45% and a negative return on equity of 110.91%. The company had revenue of $1.80 million during the quarter, compared to analysts’ expectations of $1.58 million.
Shares of Aytu Bioscience stock opened at $1.03 on Friday. Aytu Bioscience has a 12-month low of $0.68 and a 12-month high of $50.00. The stock has a market capitalization of $8.89 million, a price-to-earnings ratio of -0.04 and a beta of 4.96.
Separately, Northland Securities began coverage on shares of Aytu Bioscience in a report on Monday, October 22nd. They issued an “outperform” rating and a $10.00 target price for the company.
Aytu Bioscience Company Profile
Aytu BioScience, Inc, a specialty healthcare company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and ZolpiMist, an oral spray for the treatment of insomnia.
Receive News & Ratings for Aytu Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.